Debra E. Irwin

Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries

Abstract Objective: This retrospective study compared the real-world incidence and costs of systemic treatment-related adverse events (AEs) in patients with metastatic breast cancer in a Medicaid population. Methods: Insurance claims data for adult women who received biologic or chemotherapy (± hormonal therapy) for metastatic breast cancer between 2006–2013 were extracted from the Truven Health MarketScan® Multi-State Medicaid database. Incidence of AEs (per 100 person years) and average monthly AE-related healthcare costs (per-patient-per-month) during each line of therapy (first or later lines) were estimated. The association between AEs and total all-cause healthcare costs was estimated using multivariable regression. Results: A total of 729 metastatic breast cancer patients were analyzed. Hematological (202.3 per 100 person years) and constitutional AEs (289.6 per 100 person years) were the most common class of AEs reported. Unadjusted per-patient-per-month AE-related expenditure by class were highest for hematological AEs (

The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship

1524), followed by gastrointestinal (

Disease Severity and Baseline Characteristics of Patients Receiving Mepolizumab or Omalizumab in Employer Claims Database: A real-world experience

839) and constitutional AEs (

Real-world utilization of multiple myeloma treatments in the era of novel therapies: What is the current standard of care?

795), with anemia (

112 Healthcare Utilization and Costs for Patients With Tardive Dyskinesia

942), nausea/vomiting (

Treatment patterns and characteristics of acute promyelocytic leukemia (APL) patients receiving arsenic trioxide (ATO) therapy in a real-world setting.

699), and leukopenia/neutropenia (

Trends in survival and costs among US multiple myeloma patients.

550) having incurred the highest total AE-related costs. Adjusted total all-cause monthly costs increased with the number of AEs (

Treatment patterns and associated adverse events among patients with metastatic triple-negative breast cancer.

19,701 for >7 AEs,

Adverse event-related costs for breast cancer treatment among Medicaid patients.

16,264 for 4u2009−u20096 AEs, and

Trends in survival and costs among U.S. patients with multiple myeloma.

13,731 for 1u2009−u20093 AEs) compared to no AEs (